Coronary Artery Disease

FDA panel again rejects wider use of J&J's Xarelto

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

Jan 16, 2014
popularity not rated yet | comments 0

Latest Spotlight News

Scissoring the lipids

A new strategy which enables molecules to be disconnected essentially anywhere, even remote from functionality, is described by researchers from the University of Bristol in Nature Chemistry today. The method is now being ...